A mathematical model of monoclonal antibody therapy in leukemia

AbstractWe propose and develop a pharmacokinetic model for the quantitative analysis of dose-time-cell survival curves devolving from infusions of the murine monoclonal antibody T101 into patients with chronic lymphocytic leukemia and cutaneous T cell lymphoma. Model parameters can reflect dramatic patient-to-patient differences, though qualitative differences in model behavior across patients are slight. Our model offers tentative explanations for the dynamics of monoclonal antibody therapy in CLL and CTCL